drugset / Trial / NCT00780104
Sirolimus in Combination With MEC in High Risk Myeloid Leukemias
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the side effects of sirolimus (rapamycin) given in combination with chemotherapy (Mitoxantrone + Etoposide + Cytarabine (MEC)) on high risk myeloid leukemias.
Timeline
- Start
- 2007-07
- Primary completion
- 2010-01
- Completion
- 2010-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sirolimus | Small molecule | 4 mg | — |
| Background | Cytarabine | Small molecule | 1000 mg/m2 | Intravenous |
| Background | Etoposide | Small molecule | 100 mg/m2 | Intravenous |
| Background | Mitoxantrone | Small molecule | 8 mg/m2 | Intravenous |